HIPEC and Systemic Chemotherapy in Unresectable Peritoneal Metastases From Colorectal Cancer
Status:
Terminated
Trial end date:
2020-03-20
Target enrollment:
Participant gender:
Summary
The prognosis of patients with unresectable peritoneal metastases from colorectal cancer is
poor. These patients may obtain survival benefit from radical colorectal resection and
cytoreductive surgery (CRS). The response rates of previous conversion therapy are low.
Hyperthermic intraperitoneal chemoperfusion (HIPEC) and systemic chemotherapy are effective
methods of reducing peritoneal cancer index (PCI) levels. The purpose of this study is to
investigate the efficacy and safety of HIPEC and systemic chemotherapy in the conversion
therapy of peritoneal metastases from colorectal cancer.